|
1
|
Price M, Ballard C, Benedetti J, Neff C,
Cioffi G, Waite KA, Kruchko C, Barnholtz-Sloan JS and Ostrom QT:
CBTRUS statistical report: primary brain and other central nervous
system tumors diagnosed in the United States in 2017–2021. Neuro
Oncol. 26 (Suppl 6):vi1–vi85. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Schaff LR and Mellinghoff IK: Glioblastoma
and other primary brain malignancies in adults: A review. JAMA.
329:574–587. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Tan AC, Ashley DM, López GY, Malinzak M,
Friedman HS and Khasraw M: Management of glioblastoma: State of the
art and future directions. CA Cancer J Clin. 70:299–312.
2020.PubMed/NCBI
|
|
4
|
Klemm F, Maas RR, Bowman RL, Kornete M,
Soukup K, Nassiri S, Brouland JP, Iacobuzio-Donahue CA, Brennan C,
Tabar V, et al: Interrogation of the microenvironmental landscape
in brain tumors reveals disease-specific alterations of immune
cells. Cell. 181:1643–1660.e17. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kloosterman DJ, Erbani J, Boon M, Farber
M, Handgraaf SM, Ando-Kuri M, Sánchez-López E, Fontein B, Mertz M,
Nieuwland M, et al: Macrophage-mediated myelin recycling fuels
brain cancer malignancy. Cell. 187:5336–5356.e30. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
White J, White MPJ, Wickremesekera A, Peng
L and Gray C: The tumour microenvironment, treatment resistance and
recurrence in glioblastoma. J Transl Med. 22:5402024. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Khan F, Pang L, Dunterman M, Lesniak MS,
Heimberger AB and Chen P: Macrophages and microglia in
glioblastoma: Heterogeneity, plasticity, and therapy. J Clin
Invest. 133:e1634462023. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Miller TE, El Farran CA, Couturier CP,
Chen Z, D'Antonio JP, Verga J, Villanueva MA, Gonzalez Castro LN,
Tong YE, Saadi TA, et al: Programs, origins and immunomodulatory
functions of myeloid cells in glioma. Nature. 640:1072–1082. 2025.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Li J, Ross JL, Hambardzumyan D and Brat
DJ: Immunopathology of glioblastoma. Annu Rev Pathol. 21:135–162.
2026. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kirschenbaum D, Xie K, Ingelfinger F,
Katzenelenbogen Y, Abadie K, Look T, Sheban F, Phan TS, Li B,
Zwicky P, et al: Time-resolved single-cell transcriptomics defines
immune trajectories in glioblastoma. Cell. 187:149–165.e23. 2024.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Pombo Antunes AR, Scheyltjens I, Lodi F,
Messiaen J, Antoranz A, Duerinck J, Kancheva D, Martens L, De
Vlaminck K, Van Hove H, et al: Single-cell profiling of myeloid
cells in glioblastoma across species and disease stage reveals
macrophage competition and specialization. Nat Neurosci.
24:595–610. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wang W, Li T, Cheng Y, Li F, Qi S, Mao M,
Wu J, Liu Q, Zhang X, Li X, et al: Identification of hypoxic
macrophages in glioblastoma with therapeutic potential for
vasculature normalization. Cancer Cell. 42:815–832.e12. 2024.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Waibl Polania J, Hoyt-Miggelbrink A,
Tomaszewski WH, Wachsmuth LP, Lorrey SJ, Wilkinson DS, Lerner E,
Woroniecka K, Finlay JB, Ayasoufi K and Fecci PE: Antigen
presentation by tumor-associated macrophages drives T cells from a
progenitor exhaustion state to terminal exhaustion. Immunity.
58:232–246.e6. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Pocock J, Vasilopoulou F, Svensson E and
Cosker K: Microglia and TREM2. Neuropharmacology. 257:1100202024.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Molgora M, Liu YA, Colonna M and Cella M:
TREM2: A new player in the tumor microenvironment. Semin Immunol.
67:1017392023. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Deczkowska A, Weiner A and Amit I: The
physiology, pathology, and potential therapeutic applications of
the TREM2 signaling pathway. Cell. 181:1207–1217. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Hou J, Chen Y, Grajales-Reyes G and
Colonna M: TREM2 dependent and independent functions of microglia
in Alzheimer's disease. Mol Neurodegener. 17:842022. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Chen X, Zhao Y, Huang Y, Zhu K, Zeng F,
Zhao J, Zhang H, Zhu X, Kettenmann H and Xiang X: TREM2 promotes
glioma progression and angiogenesis mediated by microglia/brain
macrophages. Glia. 71:2679–2695. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Yu M, Chang Y, Zhai Y, Pang B, Wang P, Li
G, Jiang T and Zeng F: TREM2 is associated with tumor immunity and
implies poor prognosis in glioma. Front Immunol. 13:10892662023.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Sun R, Han R, McCornack C, Khan S, Tabor
GT, Chen Y, Hou J, Jiang H, Schoch KM, Mao DD, et al: TREM2
inhibition triggers antitumor cell activity of myeloid cells in
glioblastoma. Sci Adv. 9:eade35592023. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zheng J, Wang L, Zhao S, Zhang W, Chang Y,
Bosco DB, Huang T, Dheer A, Gao S, Xu S, et al: TREM2 mediates
MHCII-associated CD4+ T-cell response against gliomas. Neuro Oncol.
26:811–825. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zhong J, Xing X, Gao Y, Pei L, Lu C, Sun
H, Lai Y, Du K, Xiao F, Yang Y, et al: Distinct roles of TREM2 in
central nervous system cancers and peripheral cancers. Cancer Cell.
42:968–984.e9. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Park MD, Reyes-Torres I, LeBerichel J,
Hamon P, LaMarche NM, Hegde S, Belabed M, Troncoso L, Grout JA,
Magen A, et al: TREM2 macrophages drive NK cell paucity and
dysfunction in lung cancer. Nat Immunol. 24:792–801. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Chu T, Zhu G, Tang Z, Qu W, Yang R, Pan H,
Wang Y, Tian R, Chen L, Guan Z, et al: Metabolism archetype cancer
cells induce protumor TREM2+ macrophages via
oxLDL-mediated metabolic interplay in hepatocellular carcinoma. Nat
Commun. 16:67702025. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Sun R, Lei C, Xu Z, Gu X, Huang L, Chen L,
Tan Y, Peng M, Yaddanapudi K, Siskind L, et al: Neutral ceramidase
regulates breast cancer progression by metabolic programming of
TREM2-associated macrophages. Nat Commun. 15:9662024. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Lin M, Yu JX, Zhang WX, Lao FX and Huang
HC: Roles of TREM2 in the pathological mechanism and the
therapeutic strategies of Alzheimer's disease. J Prev Alzheimers
Dis. 11:1682–1695. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Yin P, Su Z, Shu X, Dong Z and Tian Y:
Role of TREM2 in immune and neurological diseases: Structure,
function, and implications. Int Immunopharmacol. 143:1132862024.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Zhao Y, Guo Q, Tian J, Liu W and Wang X:
TREM2 bridges microglia and extracellular microenvironment:
Mechanistic landscape and therapeutical prospects on Alzheimer's
disease. Ageing Res Rev. 103:1025962025. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Painter MM, Atagi Y, Liu CC, Rademakers R,
Xu H, Fryer JD and Bu G: TREM2 in CNS homeostasis and
neurodegenerative disease. Mol Neurodegener. 10:432015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Vijayan N, Thanikachalam PV and Patel S:
Decoding of the role of TREM2 in neuropathic pain: Molecular
pathway and neuroinflammatory mechanism. Drug Dev Res.
86:e701112025. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Yang H, Kim D, Yang Y, Bagyinszky E and An
SSA: TREM2 in neurodegenerative disorders: Mutation spectrum,
pathophysiology, and therapeutic targeting. Int J Mol Sci.
26:70572025. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Atagi Y, Liu CC, Painter MM, Chen XF,
Verbeeck C, Zheng H, Li X, Rademakers R, Kang SS, Xu H, et al:
Apolipoprotein E is a ligand for triggering receptor expressed on
myeloid cells 2 (TREM2). J Biol Chem. 290:26043–26050. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Filipello F, Morini R, Corradini I, Zerbi
V, Canzi A, Michalski B, Erreni M, Markicevic M, Starvaggi-Cucuzza
C, Otero K, et al: The microglial innate immune receptor TREM2 is
required for synapse elimination and normal brain connectivity.
Immunity. 48:979–991.e8. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Konishi H and Kiyama H: Non-pathological
roles of microglial TREM2/DAP12: TREM2/DAP12 regulates the
physiological functions of microglia from development to aging.
Neurochem Int. 141:1048782020. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Cignarella F, Filipello F, Bollman B,
Cantoni C, Locca A, Mikesell R, Manis M, Ibrahim A, Deng L, Benitez
BA, et al: TREM2 activation on microglia promotes myelin debris
clearance and remyelination in a model of multiple sclerosis. Acta
Neuropathol. 140:513–534. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
McCray TJ, Bedford LM, Bissel SJ and Lamb
BT: Trem2-deficiency aggravates and accelerates age-related myelin
degeneration. Acta Neuropathol Commun. 12:1542024. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Xue T, Ji J, Sun Y, Huang X, Cai Z, Yang
J, Guo W, Guo R, Cheng H and Sun X: Sphingosine-1-phosphate, a
novel TREM2 ligand, promotes microglial phagocytosis to protect
against ischemic brain injury. Acta Pharm Sin B. 12:1885–1898.
2022. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Zhao Y, Wu X, Li X, Jiang LL, Gui X, Liu
Y, Sun Y, Zhu B, Piña-Crespo JC, Zhang M, et al: TREM2 is a
receptor for β-amyloid that mediates microglial function. Neuron.
97:1023–1031.e7. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Zhong L, Wang Z, Wang D, Wang Z, Martens
YA, Wu L, Xu Y, Wang K, Li J, Huang R, et al: Amyloid-beta
modulates microglial responses by binding to the triggering
receptor expressed on myeloid cells 2 (TREM2). Mol Neurodegener.
13:152018. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Kobayashi M, Konishi H, Sayo A, Takai T
and Kiyama H: TREM2/DAP12 signal elicits proinflammatory response
in microglia and exacerbates neuropathic pain. J Neurosci.
36:11138–11150. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Wei W, Zhang L, Xin W, Pan Y, Tatenhorst
L, Hao Z, Gerner ST, Huber S, Juenemann M, Butz M, et al: TREM2
regulates microglial lipid droplet formation and represses
post-ischemic brain injury. Biomed Pharmacother. 170:1159622024.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Kawabori M, Kacimi R, Kauppinen T,
Calosing C, Kim JY, Hsieh CL, Nakamura MC and Yenari MA: Triggering
receptor expressed on myeloid cells 2 (TREM2) deficiency attenuates
phagocytic activities of microglia and exacerbates ischemic damage
in experimental stroke. J Neurosci. 35:3384–3396. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Yan Y, Bai S, Han H, Dai J, Niu L, Wang H,
Dong Q, Yin H, Yuan G and Pan Y: Knockdown of trem2 promotes
proinflammatory microglia and inhibits glioma progression via the
JAK2/STAT3 and NF-κB pathways. Cell Commun Signal. 22:2722024.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Liu T, Gao H, Xi Z, Yu T, Gu Y, Mai H,
Yuan H, Liu Y, Liu H, Zhang Q, et al: CAR-T triggers TAM
reeducation and adaptive anti-tumor response via TREM2 deficiency
or CD40 agonist. Cell Rep Med. 7:1025392026. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Ruganzu JB, Zheng Q, Wu X, He Y, Peng X,
Jin H, Zhou J, Ma R, Ji S, Ma Y, et al: TREM2 overexpression
rescues cognitive deficits in APP/PS1 transgenic mice by reducing
neuroinflammation via the JAK/STAT/SOCS signaling pathway. Exp
Neurol. 336:1135062021. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Wang M, Zhao R, Su Y, Zhai D, Liang H,
Zhang L, Wang W, Wang Z, Qi M, Jiang X, et al:
4,4′-Dimethoxychalcone mitigates neuroinflammation following
traumatic brain injury through modulation of the
TREM2/PI3K/AKT/NF-κB signaling pathway. Inflammation. 48:3487–3505.
2025. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Yang D, Sun X, Wang H, Wistuba II, Wang H,
Maitra A and Chen Y: TREM2 depletion in pancreatic cancer elicits
pathogenic inflammation and accelerates tumor progression via
enriching IL-1β+ macrophages. Gastroenterology.
168:1153–1169. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Lin H, Liu C, Hu A, Zhang D, Yang H and
Mao Y: Understanding the immunosuppressive microenvironment of
glioma: Mechanistic insights and clinical perspectives. J Hematol
Oncol. 17:312024. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Elguindy MM, Young JS, Ho WS and Lu RO:
Co-evolution of glioma and immune microenvironment. J Immunother
Cancer. 12:e0091752024. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Li J, Yu X, Yang D, Chen S, Xu J, Ma X,
Huang C, Xu B, Xue L and Wang Y: Lipid-metabolically active
TREM2high microglia-derived macrophages predict poor
prognosis and represent an immunotherapeutic target in glioma. J
Neuroimmune Pharmacol. 20:922025. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Peshoff MM, Gupta P, Oberai S, Trivedi R,
Katayama H, Chakrapani P, Dang M, Migliozzi S, Gumin J, Kadri DB,
et al: Triggering receptor expressed on myeloid cells 2 (TREM2)
regulates phagocytosis in glioblastoma. Neuro Oncol. 26:826–839.
2024. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Li P, Sun Z, Chen Y, Fang Z, Yu D, Wang L,
Ren Y and Gong P: Role of eCIRP in mediating post-ischemia
microglial phagocytosis via TREM-2 receptor: insights from porcine
and mouse cellular models. Mol Neurobiol. 63:4832026. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Zhang Z, Yu K, Cao Y, Xie P, Wang L, Shen
Z and Qin J: TREM2 facilitates gastric cancer progression and
immune evasion via inhibiting TRIM21-mediated STAT1 degradation in
tumor-associated macrophages. Cell Death Dis. 16:8452025.
View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Zhao Y, Hu H, Wang J, Hu Y, Yang L, Wu Z,
Zhao S, Wang X, Mu Y, Zheng M, et al: SYK-dependent lipid handling
in monocyte-derived macrophages governs functional recovery after
spinal cord injury. Brain Res Bull. 237:1118232026. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Colonna M: The biology of TREM receptors.
Nat Rev Immunol. 23:580–594. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Sigalov AB: TREM-1 and TREM-2 as
therapeutic targets: Clinical challenges and perspectives. Front
Immunol. 15:14989932024. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Lu J, Chu S, Wang S, Wang S, Yu Z, Yan Z,
Ji G, Zhou H, Wang J and Zhu C: Spatiotemporal and metabolic
heterogeneity of tumor-associated macrophages in glioblastoma: From
single-cell insights to therapeutic targeting. Front Cell Dev Biol.
14:17742152026. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Cheng Y, Zhao W, Xie M, Zheng X, Ding F
and Du J: Decoding myeloid heterogeneity in glioblastoma: Spatial
insights from transcriptomics. J Transl Med. 24:4322026. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Villa G, Delev D and Heiland DH: Mapping
myeloid cell function: Spatial diversity in tumor and neuronal
microenvironment. Cancer Cell. 42:934–936. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Genoud V, Marinari E, Nikolaev SI, Castle
JC, Bukur V, Dietrich PY, Okada H and Walker PR: Responsiveness to
anti-PD-1 and anti-CTLA-4 immune checkpoint blockade in SB28 and
GL261 mouse glioma models. Oncoimmunology. 7:e15011372018.
View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Ghosh S and Rothlin CV: TREM2 function in
glioblastoma immune microenvironment: Can we distinguish reality
from illusion? Neuro Oncol. 26:840–842. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Kluckova K, Kozak J, Szaboova K, Rychly B,
Svajdler M, Suchankova M, Tibenska E, Filova B, Steno J, Matejcik
V, et al: TREM-1 and TREM-2 expression on blood monocytes could
help predict survival in high-grade glioma patients. Mediators
Inflamm. 2020:17981472020. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Kluckova K, Kozak J, Szaboova K,
Suchankova M, Svajdler M, Blazickova S, Makohusova M, Steno J,
Matejcik V and Bucova M: Low serum vitamin D levels are associated
with a low percentage of TREM-2+ monocytes in low-grade gliomas and
poorer overall survival in patients with high-grade gliomas.
Bratisl Lek Listy. 122:172–178. 2021.PubMed/NCBI
|
|
64
|
Ohrfelt A, Axelsson M, Malmestrom C,
Novakova L, Heslegrave A, Blennow K, Lycke J and Zetterberg H:
Soluble TREM-2 in cerebrospinal fluid from patients with multiple
sclerosis treated with natalizumab or mitoxantrone. Mult Scler.
22:1587–1595. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Qin C, Chen M, Dong MH, Yang S, Zhang H,
You YF, Zhou LQ, Chu YH, Tang Y, Pang XW, et al: Soluble TREM2
triggers microglial dysfunction in neuromyelitis optica spectrum
disorders. Brain. 147:163–176. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Greutter L, Miller-Michlits Y, Klotz S,
Reimann R, Nenning KH, Platzek S, Krause E, Kiesel B, Widhalm G,
Langs G, et al: Frequent Alzheimer's disease neuropathological
change in patients with glioblastoma. Neurooncol Adv.
6:vdae1182024.PubMed/NCBI
|
|
67
|
Zhong L, Chen XF, Wang T, Wang Z, Liao C,
Wang Z, Huang R, Wang D, Li X, Wu L, et al: Soluble TREM2 induces
inflammatory responses and enhances microglial survival. J Exp Med.
214:597–607. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Zhang L, Xiang X, Li Y, Bu G and Chen XF:
TREM2 and sTREM2 in Alzheimer's disease: From mechanisms to
therapies. Mol Neurodegener. 20:432025. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Zheng H, Jia L, Liu CC, Rong Z, Zhong L,
Yang L, Chen XF, Fryer JD, Wang X, Zhang YW, et al: TREM2 promotes
microglial survival by activating Wnt/β-catenin pathway. J
Neurosci. 37:1772–1784. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Ma YN, Hu X, Karako K, Song P, Tang W and
Xia Y: The potential and challenges of TREM2-targeted therapy in
Alzheimer's disease: Insights from the INVOKE-2 study. Front Aging
Neurosci. 17:15760202025. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Li H, Xu D, Cai W, Liu J, Bing Z and Zhang
Q: PEGylated nanoliposomal doxorubicin conjugated with specific
TREM2 peptides for glioma-targeting therapy. Adv Healthc Mater.
14:e24030962025. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Sigalov AB: Inhibition of TREM-2 markedly
suppresses joint inflammation and damage in experimental arthritis.
Int J Mol Sci. 23:88572022. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Gallop D, Scanlon KM, Ardanuy J, Sigalov
AB, Carbonetti NH and Skerry C: Triggering receptor expressed on
myeloid cells-1 (TREM-1) contributes to bordetella pertussis
inflammatory pathology. Infect Immun. 89:e00126212021. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Zhou F, Mukherjee P, Mu J and Chen P:
Therapeutic potential of targeting macrophages and microglia in
glioblastoma. Trends Pharmacol Sci. 46:848–862. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Harwood DSL, Artzi SB, Pedersen V, Locallo
A, Lü MJS, Scheie D, Nørøxe DS, Hammouda NM, Lassen U,
Weischenfeldt J and Kristensen BW: Genomic heterogeneity drives
distinct infiltration patterns in glioblastoma. Acta Neuropathol
Commun. 14:52025. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Lemoine C, Da Veiga MA, Rogister B, Piette
C and Neirinckx V: An integrated perspective on single-cell and
spatial transcriptomic signatures in high-grade gliomas. NPJ Precis
Oncol. 9:442025. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Kim J, Zhu Y, Chen S, Wang D, Zhang S, Xia
J, Li S, Qiu Q, Lee H and Wang J: Anti-glioma effect of
ginseng-derived exosomes-like nanoparticles by active
blood-brain-barrier penetration and tumor microenvironment
modulation. J Nanobiotechnology. 21:2532023. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Wang C, Feng W, Li J, Wang J, Liu L, Ye
SH, Zhang Y, Fu J, Zheng H, Chen E, et al: Enhanced nano-vaccine
utilizing biomineralized virus-like particles for efficient
glioblastoma immunotherapy via the nose-to-brain delivery pathway.
ACS Nano. 19:21154–21168. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Kuang L, Han M, Wu X, Deng Z, Liu T, Yin
Y, Tang Y, Dong Z, Hu X, Zhu S, et al: Starting the engine and
releasing the brakes of T-cell responses: A biomimetic dendritic
cell nanoplatform for improved glioblastoma immunotherapy. ACS
Nano. 19:21365–21384. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
von Locquenghien M, Zwicky P, Xie K,
Jaitin DA, Sheban F, Yalin A, Uhlitz F, Gur C, Eshed RS, David E,
et al: Macrophage-targeted immunocytokine leverages myeloid, T, and
NK cell synergy for cancer immunotherapy. Cell. 188:7099–7117.e26.
2025. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Lago C, Gianesello M, Santomaso L, Leva G,
Ballabio C, Anderle M, Antonica F and Tiberi L: Medulloblastoma and
high-grade glioma organoids for drug screening, lineage tracing,
co-culture and in vivo assay. Nat Protoc. 18:2143–2180. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Pasupuleti V, Vora L, Prasad R, Nandakumar
DN and Khatri DK: Glioblastoma preclinical models: Strengths and
weaknesses. Biochim Biophys Acta Rev Cancer. 1879:1890592024.
View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Correia CD, Calado SM, Matos A, Esteves F,
De Sousa-Coelho AL, Campinho MA and Fernandes MT: Advancing
glioblastoma research with innovative brain organoid-based models.
Cells. 14:2922025. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Wen J, Liu F, Cheng Q, Weygant N, Liang X,
Fan F, Li C, Zhang L and Liu Z: Applications of organoid technology
to brain tumors. CNS Neurosci Ther. 29:2725–2743. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Zheng C, Wang P, Zhang D, Fang Z, Feng Y,
Chen J, Chen J, Fu Y, Yang B, Yu S, et al: A novel organoid model
retaining the glioma microenvironment for personalized drug
screening and therapeutic evaluation. Bioact Mater. 53:205–217.
2025.PubMed/NCBI
|
|
86
|
Schupper AJ and Hadjipanayis CG: Novel
approaches to targeting gliomas at the leading/cutting edge. J
Neurosurg. 139:760–768. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Gampa G, Vadlakonda R, Stefanich E, Kamath
AV, Sadekar S and Shivva V: Bridging the blood-brain barrier:
Strategies to improve delivery of biologics to tumors in the brain.
Fluids Barriers CNS. 23:252026. View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Wang N, Qing Q, Xue Y, Cai S, Zheng M,
Zhang D and Ismail M: Enhancing lipid nanoparticles-mediated RNA
delivery to glioblastoma via targeted strategies. J Control
Release. 389:1144722026. View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Arjmand B, Mojavezi AR, Kamroo A, Yazdi
RK, Rezaei-Tavirani M and Vahedi MS: Advances in intranasal
delivery of exosomes for central nervous system disorders. Mol
Neurobiol. 63:1932025. View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Pai B, Ramos SI, Cheng WS, Joshi T, Özen
E, Kulumani Mahadevan LS, Silva-Hurtado TJ, Price GA, Tome-Garcia
J, Nudelman G, et al: Spatial multiomics defines a shared tumor
infiltrative signature at the resection margin in high-grade
gliomas. Cancer Res. 85:4233–4250. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Fan H, Luo Y, Gu F, Tian B, Xiong Y, Wu G,
Nie X, Yu J, Tong J and Liao X: Artificial intelligence-based MRI
radiomics and radiogenomics in glioma. Cancer Imaging. 24:362024.
View Article : Google Scholar : PubMed/NCBI
|
|
92
|
Luo J, Pan M, Mo K, Mao Y and Zou D:
Emerging role of artificial intelligence in diagnosis,
classification and clinical management of glioma. Semin Cancer
Biol. 91:110–123. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Wang YRJ, Wang P, Yan Z, Zhou Q, Gunturkun
F, Li P, Hu Y, Wu WE, Zhao K, Zhang M, et al: Advancing presurgical
non-invasive molecular subgroup prediction in medulloblastoma using
artificial intelligence and MRI signatures. Cancer Cell.
42:1239–1257.e7. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
94
|
Morello G, La Cognata V, Guarnaccia M,
Gentile G and Cavallaro S: Artificial intelligence-driven
multi-omics approaches in glioblastoma. Int J Mol Sci. 26:93622025.
View Article : Google Scholar : PubMed/NCBI
|
|
95
|
Lin B, Tan Z, Mo Y, Yang X, Liu Y and Xu
B: Intelligent oncology: The convergence of artificial intelligence
and oncology. J Natl Cancer Cent. 3:83–91. 2022.PubMed/NCBI
|
|
96
|
Li H, Nithin C, Kmiecik S and Huang SY:
Computational methods for modeling protein-protein interactions in
the AI era: Current status and future directions. Drug Discov
Today. 30:1043822025. View Article : Google Scholar : PubMed/NCBI
|
|
97
|
Sarvepalli S and Vadarevu S: Role of
artificial intelligence in cancer drug discovery and development.
Cancer Lett. 627:2178212025. View Article : Google Scholar : PubMed/NCBI
|
|
98
|
Zhang K, Yang X, Wang Y, Yu Y, Huang N, Li
G, Li X, Wu JC and Yang S: Artificial intelligence in drug
development. Nat Med. 31:45–59. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
99
|
Ocana A, Pandiella A, Privat C, Bravo I,
Luengo-Oroz M, Amir E and Gyorffy B: Integrating artificial
intelligence in drug discovery and early drug development: A
transformative approach. Biomark Res. 13:452025. View Article : Google Scholar : PubMed/NCBI
|
|
100
|
Vecchietti LF, Wijaya BN, Armanuly A,
Hangeldiyev B, Jung H, Lee S, Cha M and Kim HM: Artificial
intelligence-driven computational methods for antibody design and
optimization. MAbs. 17:25289022025. View Article : Google Scholar : PubMed/NCBI
|
|
101
|
Wang Z, Zhang RY, Ji C, Zhang JY, Yue BT
and Wang F: Revolutionizing gastrointestinal cancer research with
artificial intelligence: From precision patient stratification to
real-world evidence. World J Gastrointest Oncol. 17:1113392025.
View Article : Google Scholar : PubMed/NCBI
|
|
102
|
Jin D, Shmatko A, Patel A, Rutz S,
Friedrich L, Banan R, Rahmanzade R, Sievers P, Hamelmann S,
Schrimpf D, et al: Hetairos is a histology-based artificial
intelligence model for predicting central nervous system tumor
methylation subtypes. Nat Cancer. Jun 10–2026.(Epub ahead of
print). View Article : Google Scholar
|
|
103
|
Zapaishchykova A, Zielke J, Tak D, Climent
Pardo JC, Mojahed-Yazdi R, Soto-Rivera CL, Liu KX, Saraf A, Ye Z,
Wang W, et al: Artificial intelligence analysis of temporalis
muscle thickness for monitoring sarcopenia and clinical outcomes in
individuals with paediatric brain tumours: A retrospective cohort
study. Lancet Digit Health. 1009732026.(Epub ahead of print).
View Article : Google Scholar : PubMed/NCBI
|
|
104
|
Ning Y, Teixayavong S, Shang Y, Savulescu
J, Nagaraj V, Miao D, Mertens M, Ting DSW, Ong JCL, Liu M, et al:
Generative artificial intelligence and ethical considerations in
health care: A scoping review and ethics checklist. Lancet Digit
Health. 6:e848–e856. 2024. View Article : Google Scholar : PubMed/NCBI
|
